COSCIENS BIOPHARMA INC (CSCI) Fundamental Analysis & Valuation

NASDAQ:CSCI • CA22112H1010

2.72 USD
-0.36 (-11.69%)
At close: Sep 3, 2025
2.59 USD
-0.13 (-4.78%)
After Hours: 9/3/2025, 8:07:43 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CSCI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

CSCI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. CSCI has a bad profitability rating. Also its financial health evaluation is rather negative. CSCI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. CSCI Profitability Analysis

1.1 Basic Checks

  • In the past year CSCI has reported negative net income.
  • In the past year CSCI has reported a negative cash flow from operations.
  • CSCI had negative earnings in each of the past 5 years.
  • In the past 5 years CSCI always reported negative operating cash flow.
CSCI Yearly Net Income VS EBIT VS OCF VS FCFCSCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -56.40%, CSCI is in line with its industry, outperforming 45.94% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -173.14%, CSCI is doing worse than 64.39% of the companies in the same industry.
Industry RankSector Rank
ROA -56.4%
ROE -173.14%
ROIC N/A
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
CSCI Yearly ROA, ROE, ROICCSCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

  • CSCI has a Gross Margin of 47.26%. This is in the better half of the industry: CSCI outperforms 75.09% of its industry peers.
  • In the last couple of years the Gross Margin of CSCI has grown nicely.
  • The Profit Margin and Operating Margin are not available for CSCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
CSCI Yearly Profit, Operating, Gross MarginsCSCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CSCI Health Analysis

2.1 Basic Checks

  • CSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CSCI has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, CSCI has more shares outstanding
  • The debt/assets ratio for CSCI has been reduced compared to a year ago.
CSCI Yearly Shares OutstandingCSCI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
CSCI Yearly Total Debt VS Total AssetsCSCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -1.29, we must say that CSCI is in the distress zone and has some risk of bankruptcy.
  • CSCI's Altman-Z score of -1.29 is in line compared to the rest of the industry. CSCI outperforms 56.09% of its industry peers.
  • CSCI has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.19, CSCI is doing worse than 68.27% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z -1.29
ROIC/WACCN/A
WACC8.9%
CSCI Yearly LT Debt VS Equity VS FCFCSCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • CSCI has a Current Ratio of 2.88. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of CSCI (2.88) is worse than 64.94% of its industry peers.
  • A Quick Ratio of 2.54 indicates that CSCI has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.54, CSCI is doing worse than 66.97% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.54
CSCI Yearly Current Assets VS Current LiabilitesCSCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CSCI Growth Analysis

3.1 Past

  • CSCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.07%, which is quite good.
  • Looking at the last year, CSCI shows a very strong growth in Revenue. The Revenue has grown by 103.93%.
  • CSCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 80.53% yearly.
EPS 1Y (TTM)13.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.45%
Revenue 1Y (TTM)103.93%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%-27.08%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CSCI Yearly Revenue VS EstimatesCSCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CSCI Yearly EPS VS EstimatesCSCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. CSCI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CSCI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSCI Price Earnings VS Forward Price EarningsCSCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSCI Per share dataCSCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CSCI Dividend Analysis

5.1 Amount

  • No dividends for CSCI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CSCI Fundamentals: All Metrics, Ratios and Statistics

COSCIENS BIOPHARMA INC

NASDAQ:CSCI (9/3/2025, 8:07:43 PM)

After market: 2.59 -0.13 (-4.78%)

2.72

-0.36 (-11.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11
Earnings (Next)11-10
Inst Owners9.04%
Inst Owner Change-100%
Ins Owners1.49%
Ins Owner ChangeN/A
Market Cap8.65M
Revenue(TTM)9.03M
Net Income(TTM)-17.56M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.96
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 0.85
EV/EBITDA N/A
EPS(TTM)-5.8
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.38
FCFYN/A
OCF(TTM)-3.82
OCFYN/A
SpS2.84
BVpS3.19
TBVpS3.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.4%
ROE -173.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.26%
FCFM N/A
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
F-Score2
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.8%
Cap/Sales 19.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.54
Altman-Z -1.29
F-Score2
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)43.14%
Cap/Depr(5y)N/A
Cap/Sales(3y)7.47%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.45%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)103.93%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%-27.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.32%
OCF growth 3YN/A
OCF growth 5YN/A

COSCIENS BIOPHARMA INC / CSCI FAQ

What is the fundamental rating for CSCI stock?

ChartMill assigns a fundamental rating of 2 / 10 to CSCI.


What is the valuation status for CSCI stock?

ChartMill assigns a valuation rating of 0 / 10 to COSCIENS BIOPHARMA INC (CSCI). This can be considered as Overvalued.


How profitable is COSCIENS BIOPHARMA INC (CSCI) stock?

COSCIENS BIOPHARMA INC (CSCI) has a profitability rating of 1 / 10.